Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA/BLADDR 2020 | Challenges and treatment advances in mHSPC

Ursula Vogl • 14 Oct 2020
PROSCA/BLADDR 2020
Genitourinary Cancer Prostate Cancer

Ursula Vogl, MD, Ente Ospedaliero Cantonale (EOC), Ticino, Switzerland, discusses treatment advances in metastatic hormone-sensitive prostate cancer (mHSPC) as well as the impact of COVID-19 on treatment approaches. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Ursula Vogl

1:35
Unmet needs in mHSPC
Ursula Vogl • 7 Oct 2020
0:38
Second-line treatment of mHSPC
Ursula Vogl • 7 Oct 2020

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals